Addressing the root cause of antimicrobial resistance.

Addressing the Root Cause of Antimicrobial Resistance2025-07-16T12:48:24-04:00

Antimicrobial resistance is projected to kill up to 10 million people a year by 2050. We won’t let this happen.

TAXIS Pharmaceuticals is developing therapies to combat antimicrobial resistance addressing the root cause of the issue, targeting the very foundation of bacterial survival. Our approach goes beyond traditional methods – we’re dismantling the cellular infrastructure, breaking down barriers, and disrupting the mechanisms that fuel antimicrobial resistance.

At TAXIS Pharmaceuticals, we envision a world where antimicrobial resistance is a thing of the past.

Our Investigational Therapeutics

Our pipeline

TAXIS is  dedicated to eliminating the threat of antimicrobial resistance across a wide range of infectious diseases. We are currently researching new classes of anti-resistance agents that employ novel mechanisms of action.

bacteria

Read our latest news and insights

Innovative Approaches to Antibiotic Resistance: The Promise of TXA709

Understanding the mechanisms behind antibiotic resistance reveals the pressing need for innovative solutions in the pharmaceutical landscape. Presenting TAXIS Pharmaceuticals' Commitment to Innovation: TXA709. TAXIS is dedicated to developing novel therapies that specifically target resistant strains of bacteria.

By |December 17th, 2024|
Go to Top